- Home
- DNTH vs BIGC Comparison
DNTH vs BIGC Comparison
Compare DNTH & BIGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- BIGC
- Stock Information
- Founded
- DNTH 2015
- BIGC 2009
- Country
- DNTH United States
- BIGC United States
- Employees
- DNTH N/A
- BIGC N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- BIGC Computer Software: Prepackaged Software
- Sector
- DNTH Health Care
- BIGC Technology
- Exchange
- DNTH Nasdaq
- BIGC Nasdaq
- Market Cap
- DNTH 565.7M
- BIGC 453.4M
- IPO Year
- DNTH N/A
- BIGC 2020
- Fundamental
- Price
- DNTH $19.50
- BIGC $5.09
- Analyst Decision
- DNTH Strong Buy
- BIGC Hold
- Analyst Count
- DNTH 8
- BIGC 6
- Target Price
- DNTH $54.33
- BIGC $7.67
- AVG Volume (30 Days)
- DNTH 418.5K
- BIGC 802.1K
- Earning Date
- DNTH 05-08-2025
- BIGC 05-08-2025
- Dividend Yield
- DNTH N/A
- BIGC N/A
- EPS Growth
- DNTH N/A
- BIGC N/A
- EPS
- DNTH N/A
- BIGC N/A
- Revenue
- DNTH $6,235,000.00
- BIGC $332,927,000.00
- Revenue This Year
- DNTH N/A
- BIGC $5.97
- Revenue Next Year
- DNTH N/A
- BIGC $5.98
- P/E Ratio
- DNTH N/A
- BIGC N/A
- Revenue Growth
- DNTH 120.63
- BIGC 7.61
- 52 Week Low
- DNTH $13.37
- BIGC $4.91
- 52 Week High
- DNTH $32.27
- BIGC $8.60
- Technical
- Relative Strength Index (RSI)
- DNTH 53.31
- BIGC 34.34
- Support Level
- DNTH $18.37
- BIGC $5.02
- Resistance Level
- DNTH $19.76
- BIGC $5.47
- Average True Range (ATR)
- DNTH 1.93
- BIGC 0.30
- MACD
- DNTH 0.45
- BIGC -0.03
- Stochastic Oscillator
- DNTH 95.93
- BIGC 16.36
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About BIGC BigCommerce Holdings Inc. Series 1
BigCommerce Holdings Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of revenue is generated from Americas-U.S.